1. A method of treating or preventing HCV infection comprising administering to a subject in need thereof a therapeutically effective amount of (i) a compound that is an inhibitor of acetyl-CoA carboxylase (ACC) or a prodrug thereof, or pharmaceutically acceptable salt or ester of said compound or prodrug and (ii) a compound that is a modulator of an HCV-associated component or a prodrug thereof, or pharmaceutically acceptable salt or ester of said compound or prodrug.
2. The method of claim 1, wherein the inhibitor of ACC inhibits ACC1, ACC2, or both ACC1 and ACC2.
3. The method of claim 1, wherein the ACC inhibitor is a compound of formula XII:
wherein:
X is \u2014(C5-C20)alkyl, \u2014O(C5-C20)alkyl, \u2014(C5-C20)haloalkyl, \u2014O(C5-C20)haloalkyl, -halo, \u2014OH, \u2014(C5-C20)alkenyl, \u2014(C5-C20)alkynyl, \u2014(C5-C20)alkoxy-alkenyl, \u2014(C5-C20)hydroxyalkyl, \u2014O(C1-C6)alkyl, \u2014CO2(C1-C6)alkyl, \u2014O(C5-C20)alkenyl, \u2014O(C5-C20)alkynyl, \u2014O(C5-C20)cycloalkyl, \u2014S(C5-C20)alkyl, \u2014NH(C5-C20)alkyl, \u2014NHCO(C5-C20)alkyl, \u2014N(C1-C6)alkylCO(C5-C20)alkyl or \u2014O(C5-C20)alkoxy; and
Y is O, S, \u2014NH or N(C1-C6)alkyl.
4. The method of claim 3, wherein the ACC inhibitor is TOFA.
5. The method of claim 1, wherein the ACC inhibitor is a compound of formula XIII:
wherein A-B is N\u2014CH or CH\u2014N; K is (CH2)r wherein r is 2, 3 or 4; m and n are each independently 1, 2 or 3 when A-B is N\u2014CH or m and n are each independently 2 or 3 when A-B is CH\u2014N; the dashed line represents the presence of an optional double bond;
D is carbonyl or sulfonyl;
E is either a) a bicyclic ring consisting of two fused fully unsaturated five to seven membered rings, taken independently, each of said rings optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or b) a tricyclic ring consisting of two fused fully unsaturated five to seven membered rings, taken independently, each of said rings optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, said two fused rings fused to a third partially saturated, fully unsaturated or fully saturated five to seven membered ring, said third ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen; or c) a tetracyclic ring comprising a bicyclic ring consisting of two fused fully unsaturated five to seven membered rings, taken independently, each of said rings optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, said bicyclic ring fused to two fully saturated, partially saturated or fully unsaturated five to seven membered monocyclic rings taken independently, each of said rings optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen or said bicyclic ring fused to a second bicyclic ring consisting of two fused fully saturated, partially saturated or fully unsaturated five to seven membered rings, taken independently, each of said rings optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen; or d) a teraryl ring comprising a fully unsaturated five to seven membered ring, said ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, and said ring di-substituted independently with a fully unsaturated five to seven membered ring to form a teraryl nonfused ring system, each of said substituent rings optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said E bi-, tri- or tetra cyclic ring or teraryl ring is optionally mono-, di- or tri-substituted independently on each ring used to form the bi-, tri- or tetra cyclic ring or teraryl ring with halo, hydroxy, amino, cyano, nitro, oxo, carboxy, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C4) alkylthio, (C1-C6) alkoxycarbonyl;
wherein said E bi-, tri- or tetra-cyclic ring or teraryl ring is optionally mono-substituted with a partially saturated, fully saturated or fully unsaturated three to eight membered ring R10 optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen or a bicyclic ring R\u2033 consisting of two fused partially saturated, fully saturated or fully unsaturated three to eight membered rings, taken independently, each of said rings optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, said R10 and R\u2033 rings optionally additionally bridged and said R10 and R\u2033 rings optionally linked through a fully saturated, partially unsaturated or fully unsaturated one to four membered straight or branched carbon chain wherein the carbon (s) may optionally be replaced with one or two heteroatoms selected independently from oxygen, nitrogen and sulfur, provided said E bicyclic ring has at least one substituent and the E bicyclic ring atom bonded to D is carbon; wherein said R10 or R\u2033ring is optionally mono-, di- or tri-substituted independently with halo, hydroxy, amino, cyano, nitro, oxo, carboxy, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C4)alkylthio, (C1-C6) alkoxycarbonyl, (C1-C6) alkylcarbonyl, (C1-C6) alkylcarbonylamino, or mono-N\u2014 or di-N,N\u2014(C1-C6) alkylamino or mono-N\u2014 or di-N,N\u2014(C1-C6) alkylaminocarbonyl wherein said (C1-C6) alkyl and (C1-C6) alkoxy substituents are also optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C1-C6) alkoxy, amino, mono-N\u2014 or di-N,N\u2014(C1-C6) alkylamino or from one to nine fluorines;
G is carbonyl, sulfonyl or CR7R8; wherein R7 and R8 are each independently H, (C1-C6) alkyl, (C2-C6) alkenyl or (C2-C6) alkynyl or a five to seven membered partially saturated, fully saturated or fully unsaturated ring optionally having one heteroatom selected from oxygen, sulfur and nitrogen;
J is OR\u2032, NR2R3 or CR4R5R6; wherein R\u2032, R2 and R3 are each independently H, Q, or a (C1-C10) alkyl, (C3-C10) alkenyl or (C3-C10) alkynyl substituent wherein said carbon(s) may optionally be replaced with one or two heteroatoms selected independently from oxygen, nitrogen and sulfur and wherein said sulfur is optionally mono- or di-substituted with oxo, said carbon (s) is optionally mono-substituted with oxo, said nitrogen is optionally di-substituted with oxo, said carbon (s) is optionally mono-, di- or tri-substituted independently with halo, hydroxy, amino, nitro, cyano, carboxy, (C1-C4) alkylthio, (C1-C6)alkyloxycarbonyl, mono-N\u2014 or di-N,N\u2014(C1-C6) alkylamino or mono-N\u2014 or di-N,N\u2014(C1-C6)alkylaminocarbonyl; and said chain is optionally mono-substituted with Q1; wherein Q and Q1 are each independently a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen or a bicyclic ring consisting of two fused or spirocyclic partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, said bicyclic ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, said mono or bicyclic ring optionally additionally bridged with (C1-C3) alkylen wherein said (C1-C3) alkylen carbons are optionally replaced with one to two heteroatoms selected independently from oxygen, sulfur and nitrogen; wherein said Q and Q1 ring are each independently optionally mono-, di-, tri-, or tetra-substituted independently with halo, hydroxy, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C4) alkylthio, (C1-C6) alkylcarbonyl, (C1-C6) alkylcarbonylamino, (C1-C6)alkyloxycarbonyl, mono-N\u2014 or di-N,N\u2014(C1-C6) alkylamino, mono-N\u2014 or di-N,N\u2014(C1-C6)alkylaminosulfonyl, mono-N\u2014 or di-N,N\u2014(C1-C6) alkylaminocarbonyl, wherein said (C1-C6) alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkoxy, (C1-C4) alkylthio, (C1-C6)alkyloxycarbonyl or mono-N\u2014 or di-N,N\u2014(C1-C6)alkylamino wherein said (C1-C6) alkyl substituent is also optionally substituted with from one to nine fluorines;
or wherein R2 and R3 can be taken together with the nitrogen atom to which they are attached to form a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to three additional heteroatoms selected independently from oxygen, sulfur and nitrogen or a bicyclic ring consisting of two fused, bridged or spirocyclic partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, said bicyclic ring optionally having one to three additional heteroatoms selected independently from oxygen, sulfur and nitrogen or a tricyclic ring consisting of three fused, bridged or spirocyclic partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, said tricyclic ring optionally having one to three additional heteroatoms selected independently from oxygen, sulfur and nitrogen; wherein said NR2R3 ring is optionally mono-, di-, tri- or tetra-substituted independently with R15, halo, hydroxy, amino, nitro, cyano, oxo, carboxy, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C4) alkylthio, (C1-C6) alkylcarbonylamino or mono-N\u2014 or di-N,N\u2014(C1-C6) alkylamino, wherein said (C1-C6) alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, amino, nitro, cyano, oxo, carboxy, (C1-C6) alkoxy, (C1-C4) alkylthio, (C1-C6) alkyloxycarbonyl, mono-N\u2014 or di-N,N\u2014(C1-C6) alkylamino, said (C1-C6) alkyl substituent is also optionally substituted with from one to nine fluorines;
wherein three heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said ring is optionally mono-, di- or tri-substituted with halo, hydroxy, amino, nitro, cyano, oxo, carboxy, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C4)alkylthio, (C1-C6) alkoxy, (C1-C6)alkylcarbonylamino, mono-N\u2014 or di-N,N\u2014(C1-C6) alkylamino; wherein said NR2R3 ring is optionally substituted with a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, said bicyclic ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, said mono or bicyclic ring optionally additionally bridged said ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said (C1-C6) alkyl and said ring are optionally mono-, di- or tri-substituted with halo, hydroxy, amino, nitro, cyano, oxo, carboxy, (C2-C6) alkenyl, (C3-C6) alkynyl, (C1-C6) alkylcarbonylamino, hydroxy, (C1-C6) alkoxy, (C1-C4) alkylthio, (C1-C6) alkoxy, mono-N\u2014 or di-N,N\u2014(C1-C6) alkylamino; wherein R4, R5 and R6 are independently H, halo, hydroxy, (C1-C6) alkyl or R4 and R5 are taken together to form a partially saturated, fully saturated or fully unsaturated three to eight membered ring, said ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said (C1-C6) alkyl and said ring are optionally mono-, di- or tri-substituted with halo, hydroxy, amino, nitro, cyano, oxo, carboxy, (C2-C6) alkenyl, (C3-C6) alkynyl, (C1-C6) alkylcarbonylamino, hydroxy, (C1-C6) alkoxy, (C1-C4) alkylthio, (C1-C6) alkoxy, mono-N\u2014 or di-N,N\u2014(C1-C6) alkylamino with the proviso that 1\u2032-(anthracene-9-carbonyl)-1,4\u2032bipiperidinyl-3-carboxylic aciddiethyiamide; 1\u2032-(1-oxa-2,3-diaza-cyclopentaanaphthalene-5-sulfonyl)-1,4\u2032bipiperidinyl-3 carboxylic acid diethylamide; 1\u2032-(5-dimethylamino-naphthalene-1-sulfonyl)-1,4\u2032bipiperidinyl-3-carboxylic acid diethylamide; 1\u2032-(9,10,10-trioxo-9,10-dihydro-thioxanthene-3-carbonyl)-1-4\u2032bipiperidinyl-3-carboxylic acid diethylamide; and 1\u2032-(2-Oxo-2H-chromen-3-carbonyl)-1,4\u2032bipiperidinyl-3-carboxylic acid diethylamide are not included.
6. The method of claim 5, wherein the ACC inhibitor is CP-610431.
7. The method of claim 5, wherein the ACC inhibitor is CP-640186.
8. The method of claim 1, wherein an immunomodulator is also administered to the subject.
9. The method of claim 8, wherein the immunomodulator is one or more of Pegasys, Roferon-A, Pegintron, Intron A, Albumin IFN-\u03b1, locteron, Peginterferon-\u03bb, omega-IFN, medusa-IFN, belerofon, infradure, Interferon alfacon-1, and Veldona.
10. The method of claim 1, wherein one or more of ribavirin or a ribavirin analog selected from taribavirin, mizoribine, merimepodib, mycophenolate mofetil, and mycophenolate is also administered to the subject.
11. A method of treating or preventing HCV infection comprising administering to a subject in need thereof a therapeutically effective amount of (i) a compound that is a modulator of a host cell target or a prodrug thereof, or pharmaceutically acceptable salt or ester of said compound or prodrug and (ii) a compound that is a modulator of an HCV-associated component or a prodrug thereof, or pharmaceutically acceptable salt or ester of said compound or prodrug.
12. The method of claim 11, wherein an immunomodulator is also administered to the subject.
13. The method of claim 12, wherein the immunomodulator is one or more of Pegasys, Roferon-A, Pegintron, Intron A, Albumin IFN-\u03b1, locteron, Peginterferon-\u03bb, omega-IFN, medusa-IFN, belerofon, infradure, Interferon alfacon-1, and Veldona.
14. The method of claim 11, wherein one or more of ribavirin or a ribavirin analog selected from taribavirin, mizoribine, merimepodib, mycophenolate mofetil, and mycophenolate is also administered to the subject.
15. The method of claim 11, wherein the compound that is a modulator of a host cell target is an inhibitor of an acyl-CoA:cholesterol acyl-transferase (ACAT).
16. The method of claim 15 wherein the inhibitor of ACAT inhibits ACAT1, ACAT2, or both ACAT1 and ACAT2.
17. The method of claim 15, wherein the ACAT inhibitor is pactimibe, Compound 1, Compound 21, Compound 12g, SMP-797, CL-283,546, Wu-V-23 or eflucimibe.
18. The method of claim 15 wherein the inhibitor of ACAT is a compound of formula V:
wherein
X and Y are independently selected from N and CH;
R1\u2032 and R2\u2032 are independently selected from H, C1-6 alkyl which may be optionally substituted with F, OCH3 and OH, and C1-6 cycloalkyl;
R6 and R7 are independently selected from H, and C1-3 alkyl, or R6 and R7 taken together may form a C3-6 cycloalkyl;
R3, R4 and R5 are independently selected from H, C1-6 alkyl which may be optionally substituted with F, OCH3 and OH, and C1-6 cycloalkyl;
additionally or alternatively, one of R6 or R7 may be taken together with R5 to form a C5-11 cycloalkyl ring.
19. The method of claim 18, wherein the compound is avasimibe.
20. (canceled)
21. (canceled)
22. (canceled)
23. The method of claim 11, wherein the compound that is a modulator of a host cell target is an inhibitor of a long-chain acyl-CoA synthetase (ACSL).
24. The method of claim 23, wherein the ACSL inhibitor is a compound of formula I:
wherein R1 is a carbon chain having from 3 to 23 atoms and heteroatoms;
wherein the carbon chain comprises 0-10 double bonds and 0-4 heteroatoms; and
wherein 0-8 of the carbon atoms of R1 are optionally substituted.
25. The method of claim 23, wherein the ACSL inhibitor is triacsin C.
26. (canceled)
27. (canceled)
28. (canceled)
29. The method of claim 11, wherein the compound that is a modulator of a host cell target is an inhibitor of an elongase (ELOVL).
30. The method of claim 29, wherein the inhibitor of an elongase is an inhibitor of one or more of ELOVL2, ELOVL3, ELOVL6.
31. (canceled)
32. (canceled)
33. (canceled)
34. The method of claim 11, wherein the compound that is a modulator of a host cell target is an inhibitor of fatty acid synthase (FAS).
35. The method of claim 34, wherein the inhibitor of fatty acid synthase is C75 or orlistat.
36. (canceled)
37. (canceled)
38. (canceled)
39. The method of claim 11, wherein the compound that is a modulator of a host cell target is an inhibitor of HMG-CoA reductase.
40. The method of claim 39, wherein the HMG-CoA reductase inhibitor is fluvastatin, lovastatin, mevastatin, lovastatin, pravastatin, simvastatin, atorvastatin, itavastatin, or visastatin.
41. (canceled)
42. (canceled)
43. (canceled)
44. The method of claim 11, wherein the compound that is a modulator of a host cell target is an inhibitor of lipid droplet formation.
45. The method of claim 44, wherein the inhibitors of lipid droplet accumulation is PF-1052, spylidone, sespendole, terpendole C, rubimaillin, Compound 7, Compound 8, Compound 9, vermisporin; beauveriolides; phenochalasins; isobisvertinol; or K97-0239.
46. (canceled)
47. (canceled)
48. (canceled)
49. The method of claim 11, wherein the compound that is a modulator of a host cell target an inhibitor of serine palmitoyl transferase (SPT).
50. The method of claim 49, wherein the inhibitor of SPT is myriocin, sphingofungin B, sphingofungin C, sphingofungin E sphingofungin F, lipoxamycin, viridiofungin A, sulfamisterin, or NA255.
51. (canceled)
52. (canceled)
53. (canceled)
54. The method of claim 1, wherein the modulator of an HCV-associated component is an HCV protease inhibitor.
55. The method of claim 54, wherein the HCV protease inhibitor is selected from boceprevir, telaprevir, ITMN-191, SCH-900518, TMC-435, BI-201335, MK-7009, VX-500, VX-813, BMS650032, VBY376, R7227, VX-985, ABT-333, ACH-1625, ACH-2684, GS-9256, GS-9451, MK-5172, and ABT-450.
56. The method of claim 54, wherein the HCV protease inhibitor is boceprevir or telaprevir.
57. The method of claim 1, wherein the modulator of an HCV-associated component is an HCV helicase (NS3) inhibitor.
58. The method of claim 57, wherein the modulator of an HCV-associated component is an HCV helicase (NS3) inhibitor selected from compounds of the following structure
wherein X is N, R4 is H and R5 is CH3; X is CH, R4 is H and R5 is CH3; or X is CH, R4 is CH3 and R5 is H.
59. The method of claim 57, wherein the modulator of an HCV-associated component is an HCV helicase (NS3) inhibitor selected from
60. The method of claim 57, wherein the modulator of an HCV-associated component is an HCV helicase (NS3) inhibitor selected from
61. The method of claim 1, wherein the modulator of an HCV-associated component is an inhibitor HCV nonstructural protein 4B (NS4B).
62. The method of claim 61, wherein the inhibitor of NS4B is GSK-8853, clemizole, a benzimidazole RBI (B-RBI) or an indazole RBI (I-RBI).
63. The method of claim 1, wherein the modulator of an HCV-associated component is an inhibitor HCV nonstructural protein 5A (NS5A)
64. The method of claim 63, wherein the inhibitor of NS5A is BMS-790052, A-689, A-831, EDP239, GS5885, GSK805, PPI-461 BMS-824393 or ABT-267.
65. The method of claim 1, wherein the modulator of an HCV-associated component is an inhibitor of HCV polymerase (NS5B).
66. The method of claim 65, wherein the inhibitor of NS5B is a nucleoside analog, a nucleotide analog, or a non-nucleoside inhibitor.
67. The method of claim 65, wherein the inhibitor of NS5B is valopicitabine, R1479, R1626, R7128, RG7128, TMC649128, IDX184, PSI-352938, INX-08189, GS6620, filibuvir, HCV-796, VCH-759, VCH-916, ANA598, VCH-222 (VX-222), BI-207127, MK-3281, ABT-072, ABT-333, GS9190, BMS791325, GSK2485852A, PSI-7851, PSI-7976, and PSI-7977.
68. The method of claim 1, wherein the modulator of an HCV-associated component is an inhibitor of HCV viral ion channel forming protein (p7).
69. The method of claim 69, wherein the inhibitor of p7 is BIT225 or HPH116.
70. The method of claim 1, wherein the modulator of an HCV-associated component is an IRES inhibitor.
71. The method of claim 70, wherein the IRES inhibitor is Mifepristone, Hepazyme, ISIS14803, and siRNAsshRNAs.
72. The method of claim 1, wherein the modulator of an HCV-associated component is an HCV entry inhibitor.
73. The method of claim 72, wherein the HCV entry inhibitor is HuMax HepC, JTK-652, PRO206, SP-30, or ITX5061.
74. The method of claim 1, wherein the modulator of an HCV-associated component is a cyclosporin inhibitor.
75. The method of claim 74, wherein the cyclophilin inhibitor is Debio 025, NIM811, SCY-635, or cyclosporin-A.
76. The method of claim 1, wherein the modulator of an HCV-associated component is modulator of microRNA-122 (miR-122).
77. The method of claim 76 wherein the modulator of microRNA-122 is SPC3649.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An image forming apparatus comprising:
a body;
a holding member configured to be movable between a housing position where the holding member is accommodated in the body, and a drawn-out position where the holding member is drawn out to an outside of the body;
a first cartridge configured to be attached to the holding member along a first attachment path, so that the first cartridge is placed at first image forming position and is held in the holding member;
a second cartridge configured to be attached to the holding member along a second attachment path, so that the second cartridge is placed at image forming position and is held in the holding member;
a first restricting member is disposed correspondingly with the first cartridge;
a second restricting member is disposed correspondingly with the second cartridge; and
wherein the first cartridge and the second cartridge are arranged in a movement direction of the holding member,
wherein in a state where the holding member is drawn out to the drawn-out position, the first restricting member is located at first unrestricted position that is retracted from the first attachment path and the second restricting member is located at second unrestricted position that is retracted from the second attachment path, and
wherein in an attachment process in which the holding member is moved from the drawn-out position to the housing position, the first restricting member is advanced from the first unrestricted position to a first restricting position on the attachment path to restrict the first cartridge from being detached from the first image forming position and the second restricting member is advanced from the second unrestricted position to a second restricting position on the attachment path to restrict the second cartridge from being detached from the second image forming position.
2. The image forming apparatus according to claim 1 further comprising a butting member disposed in the body,
wherein the first and second restricting members at the first and second unrestricted positions are projected from the holding member, and, in the attachment process, portions which are projected from the holding member butt against the butting member to move the first and second restricting members from the first and second unrestricted positions to the first and second restricting positions, respectively.
3. The image forming apparatus according to claim 1 further comprising a first urging member which urges the first restricting members toward the first unrestricted positions.
4. The image forming apparatus according to claim 3 further comprising a second urging member which urges the second restricting member toward the second unrestricted position.
5. The image forming apparatus according to claim 1, wherein the first cartridge has a first case and a first restricted portion which is outward projected from the first case,
wherein the second cartridge has a second case and a second restricted portion which is outward projected from the second case,
the first restricting member at the first restricting position is opposed to the first restricted portion of the first cartridge which is placed at the first image forming position while a first predetermined gap is formed between the first restricting member and the first cartridge, and
the second restricting member at the second restricting position is opposed to the second restricted portion of the second cartridge which is placed at the second image forming position while a second predetermined gap is formed between the second restricting member and the second cartridge.
6. The image forming apparatus according to claim 5, wherein a length of the first predetermined gap is the same as that of the second predetermined gap.
7. The image forming apparatus according to claim 5 further comprising first and second pressing members configured to respectively press the first and second cartridges placed at the image forming positions to position the first and second cartridge with respect to the holding member, and
the first attachment path includes:
a first path through which the first cartridge is passed when first cartridge is displaced between an attachment posture that is formed when the first cartridge is placed at the image forming position, and a release posture which is formed when the pressing on the first cartridge is released; and
a second path through which the first cartridge is passed when the first cartridge is to be displaced between the release posture and a state where the first cartridge is detached from the holding member, and
the second attachment path includes
a third path through which the second cartridge is passed when the second cartridge is displaced between an attachment posture that is formed when the second cartridge is placed at the image forming position, and a release posture which is formed when the pressing on the second cartridge is released; and
a fourth path through which the second cartridge is passed when the second cartridge is to be displaced between the release posture and a state where the second cartridge is detached from the holding member.
8. The image forming apparatus according to claim 7, wherein
the first restricting member at the restricting position advances into the first path,
the first restricting member is placed downstream of the first restricted portion in a direction of movement of the first cartridge when the first cartridge is displaced from the attachment posture to the release posture,
the second restricting member at the restricting position advances into the third path,
the second restricting member is placed downstream of the second restricted portion in a direction of movement of the second cartridge when the second cartridge is displaced from the attachment posture to the release posture.
9. The image forming apparatus according to claim 7 further comprising a separating member configured to move the first and second cartridges in the attachment posture, in a direction opposite to a direction of the pressing by the first and second pressing members.
10. The image forming apparatus according to claim 1 further comprising first and second photosensitive members configured to be held by the holding member, the first and second photosensitive members being arranged side by side in the movement direction, and extending in a direction perpendicular to the movement direction, and
the first cartridge includes a first developing cartridge which is disposed correspondingly with the first photosensitive member, and which has a developer carrier each carrying a developer that is to be supplied to the first photosensitive member, and
the second cartridge includes a second developing cartridge which is disposed correspondingly with the second photosensitive member, and which has a developer carrier each carrying a developer that is to be supplied to the second photosensitive member.
11. The image forming apparatus according to claim 10, wherein
the holding member includes, in one end side of the first and second photosensitive members in the extending direction, a positioning portion configured to position the holding member with respect to the body, and
the first and second restricting members are disposed on the other end side of the holding member in the extending direction.